Regeneron's First Global Day of Service Supports Over 100 Non-Profit and Community Organizations
TARRYTOWN, N.Y., Oct. 27, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today celebrated the company's first ever global Day for Doing Good, a company-wide day of service. Regeneron colleagues are participating in more than 225 community service projects that will impact over 100 non-profit and community organizations. The effort involves thousands of Regeneron colleagues from sites in Westchester County and the Capital Region in New York, Basking Ridge in New Jersey, and Limerick and Dublin in Ireland, as well as field-based employees.
"At Regeneron we have a tradition of 'doing well by doing good' – it's what we commit to every day through our work developing and producing medicines for serious diseases and through our efforts to strengthen our communities," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron. "Day for Doing Good unites our more than 6,000 employees around the shared goal of making a difference in our world."
"As our company expands, we have the incredible opportunity to further extend Regeneron's already significant positive social impact," said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron. "In addition to volunteerism inititiaves such as Day for Doing Good, we provide significant support for local and national programs, such as the Regeneron Science Talent Search, that build a pipeline of future scientific innovators. We also support patient communities impacted by a wide range of serious diseases."
Day for Doing Good projects cover multiple impact areas and include opportunities such as sorting donated items for refugees in Albany, NY, working with Head Start preschoolers on science and literacy activities in Westchester, NY, and conducting landscape and facility improvement at a therapy facility for children with special needs in County Clare, Ireland.
Day for Doing Good highlights:
- More than 50% of Regeneron employees participating
- Over 3,500 employees volunteering
- More than 10,000 volunteer hours
- 105 non-profit organizations reached through 227 different volunteer projects
- Tens of thousands of people potentially benefiting
"Regeneron's Day for Doing Good is the largest corporate volunteer initiative that Volunteer New York! has ever coordinated in the Westchester region and represents Regeneron's ever-increasing commitment to creating positive change in its local communities," said Alisa Kesten, Executive Director of Volunteer New York!, the organization facilitiating Regeneron's Day for Doing Good volunteer projects in Westchester County. "Regeneron's dedication to community involvement has only grown with the company's rapid growth."
Regeneron corporate citizenship programs also include the title sponsorship of the Regeneron Science Talent Search, the nation's most prestigious science and math competition for high school seniors (known as the Westinghouse STS from 1942-1998 and the Intel STS from 1998-2016), for which Regeneron has pledged $100 million over 10 years. Additionally, Regeneron supports many local and national initiatives for Science, Technology, Engineering and Math (STEM) education, with a commitment to supporting top student talent, diversifying the talent pool and increasing access to STEM education for underrepresented populations. Beyond STEM, Regeneron empowers employees to give back through Regeneron in the Community, a year-round volunteer program.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for nearly 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to six FDA-approved treatments and over a dozen product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, including VelocImmune® to yield optimized fully-human antibodies, and ambitious initiatives such as the Regeneron Genetics Center, one of the largest genetics sequencing efforts in the world. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
Regeneron Media Relations
Ella Campbell
Tel: +1 (914) 847-7017
[email protected]
SOURCE Regeneron Pharmaceuticals, Inc.
Share this article